Muutke küpsiste eelistusi

Drug Resistance in Oncology [Kõva köide]

Edited by (UCLA/ Sepulveda VAMC, Sepulveda, California, USA)
  • Formaat: Hardback, 416 pages, kõrgus x laius: 280x210 mm, kaal: 930 g
  • Sari: Basic and Clinical Oncology
  • Ilmumisaeg: 21-Aug-1997
  • Kirjastus: CRC Press Inc
  • ISBN-10: 0824792955
  • ISBN-13: 9780824792954
Teised raamatud teemal:
Drug Resistance in OncologySuurem pilt
  • Formaat: Hardback, 416 pages, kõrgus x laius: 280x210 mm, kaal: 930 g
  • Sari: Basic and Clinical Oncology
  • Ilmumisaeg: 21-Aug-1997
  • Kirjastus: CRC Press Inc
  • ISBN-10: 0824792955
  • ISBN-13: 9780824792954
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780824792954.html
Märksõnad:
Brings together work by laboratory scientists and clinicians on mechanisms of resistance of specific cancers to various chemotherapeutic drugs. Explores the relationship between the differentiation phenotypes and response to chemotherapy, emphasizes the mechanisms of drug resistance in different histological types of cancer, and presents strategies for overcoming drug resistance in various tumor types. Subjects include resistance in small cell and non-small cell lung cancer, targeting of drugs using liposomes, and breast cancer resistance to hormone and cytotoxic agents. For clinicians and researchers. Annotation c. by Book News, Inc., Portland, Or.

Arvustused

" this book is a very timely update on mechanisms of drug resistance. It is quite comprehensive and is recommended for the clinician engaged in clinical research to whom it will provide an excellent review on the subject. "-ASCO OnLine

Series Introduction v(2) Preface vii(2) Contributors xi Part I. Respiratory Cancer 1(106)
1. Chemotherapy Resistance in Small Cell Lung Cancer: Consequences for the Clinician and Future Prospects 1(26) Bonne Biesma Egbert F. Smit Pieter E. Postmus
2. Multidrug Resistance in Small Cell Lung Cancer 27(50) Shelagh E. L. Mirski Susan P. C. Cole
3. Correlations Between Clinical Outcomes and In Vitro Chemosensitivity Testing in Non-Small Cell Lung Cancer 77(10) David W. Wilbur
4. Liposomal Formulations of Chemotherapeutic Drugs 87(20) Samuel D. Bernal Yuk-Chor Wong Romulo de Villa Gloria Bernas Part II. Breast Cancer 107(84)
5. Tamoxifen Resistance and Breast Cancer 107(20) Lin Soe Michael W. DeGregorio
6. Resistance to Endocrine Therapy in Breast Cancer 127(40) Per E. LXXXnning
7. Heat Shock Proteins and Drug Resistance in Breast Cancer 167(24) Daniel R. Ciocca Laura M. Vargas Roig Part III. Other Epithelial Cancers 191(36)
8. Overcoming Drug Resistance in Ovarian Cancer 191(24) P. H. B. Willemse G. J. Veldhuis A. G. J. van der Zee E. G. E. de Vries
9. Protein Kinase C Activation and the Intrinsic Drug Resistance of Human Colon Cancer 215(62) Catherine A. OBrian Karen R. Gravitt Nancy E. Ward Krishna P. Gupta Philip J. Bergman Constantin G. Ioannides Part IV. Hematological Malignancies 227(52)
10. Clinical Relevance of P-glycoprotein-Related Multidrug Resistance in Hematological Malignancies 227(22) Petra C. Pasman Harry C. Shouten
11. Prediction of Cytotoxic Drug Resistance in Acute Leukemia 249(30) Rolf Larsson Part V. Mechanisms of Drug Resistance 279(116)
12. Determinants of Estramustine Resistance 279(16) Lisa A. Speicher Kenneth D. Tew
13. Strategies for Overcoming Anthracycline Resistance 295(36) Daniel J. Booser
14. Cellular Mechanisms of Cisplatin Resistance 331(32) Jeroen Oldenburg Gerrit Los
15. Radiation Response in Chemotherapy-Resistant Tumors 363(14) Patrick Miller Michael Nejad David S. Shimm
16. Preclinical In Vivo Models of Drug Resistance 377(18) Beverly A. Teicher Index 395